Adalimumab biosimilars face product obsolescence before launch

Center for Biosimilars

 6 January 2021 - Product differentiation by concentration is a threat to the multiple adalimumab biosimilars approved but not yet launched.

Multiple biosimilar developers have obtained FDA approval for biosimilar versions of adalimumab, an immunosuppressive drug for rheumatologic and gastro-intestinal disorders, but won’t be able to bring these products to market until 2023, based on deals struck with AbbVie, which markets Humira, the blockbuster adalimumab innovator product. 

One question is whether these approved biosimilars will still be relevant 2 years from now.

Read Center for Biosimilars article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Biosimilar